BrightSpring Health price target raised to $41 from $30 at BTIG

BTIG analyst David Larsen raised the firm’s price target on BrightSpring Health (BTSG) to $41 from $30 and keeps a Buy rating on the shares after its Q3 earnings beat. The higher revenue guidance continues to be driven by solid momentum in Pharmacy, with infusion and specialty growing at a very rapid pace, and the firm continues to be impressed by BrightSpring’s broad strength and growth across the entire business, driven by high quality care, a growing market, and thoughtful and strategic leadership, the analyst tells investors in a research note.